Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof

{
  "publication_number": "US6080751A",
  "country": "US",
  "kind": "A",
  "title": "Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof",
  "abstract": "A method of treating human pancreatic cancer with water-insoluble 20(S)-camptothecin compounds with the closed-lactone ring intact and/or derivatives thereof is disclosed. The method includes preferably administering the compounds intramuscularly, orally, and transdermally.",
  "claims": [
    "1. A method of treating pancreatic cancer in a human comprising administering to said human an effective amount of a water-insoluble 20(S)-camptothecin compound with a closed-lactone ring, a derivative thereof or mixture thereof, wherein said 20(S)-camptothecin compound is 20(S)-camptothecin, 9-Nitro-20(S)-camptothecin, 9-Amino-20(S)-camptothecin, or a mixture thereof, and wherein said effective amount is at least about 1 mg/day.",
    "2. The method of claim 1, wherein said 20(S)-camptothecin compound is 9-Nitro-20(S)-camptothecin.",
    "3. The method of claim 1, wherein said 20(S)-camptothecin compound is administered orally.",
    "4. The method of claim 1, wherein said 20(S)-camptothecin compound is administered or intramuscularly.",
    "5. The method of claim 1, wherein said 20(S)-camptothecin compound is administered transdermally.",
    "6. The method of claim 1, wherein said 20(S)-camptothecin compound is 9-amino-20(S)-camptothecin.",
    "7. The method of claim 1, wherein said 20(S)-camnptothecin compound is 20(S)-camptothecin.",
    "8. The method of claim 1, wherein said effective amount is from about 1 mg/day to about 4 mg/day.",
    "9. The method of claim 1, wherein said effective amount is from 1 mg/day to 4 mg/day."
  ],
  "cpc": [
    "A61K 31/44",
    "A61K 31/4745",
    "C07D 491/22"
  ],
  "assignees": [
    "STEHLIN FOUNDATION FOR CANCER"
  ],
  "filing_date": "1996-09-13",
  "publication_date": "2000-06-27",
  "grant_date": "2000-06-27",
  "priority_date": "1992-01-14",
  "application_number": "US-71339296-A",
  "family_id": "27485214",
  "citations": [
    "EP0074256A1",
    "EP0220601A1",
    "EP0418099A2",
    "EP0540099A1",
    "JPH06150985A",
    "JPS59501288A",
    "JPS5951289A",
    "JPS595188A",
    "JPS6185319A",
    "JPS6185389A",
    "US32518A",
    "US3894029A",
    "US4031098A",
    "US4357422A",
    "US4399276A",
    "US4399282A",
    "US4473692A",
    "US4513138A",
    "US4545880A",
    "US4604463A",
    "US4774236A",
    "US4867978A",
    "US4874779A",
    "US4894456A",
    "US4904768A",
    "US4914205A",
    "US4939255A",
    "US4943579A",
    "US4981968A",
    "US5004758A",
    "US5041424A",
    "US5049668A",
    "US5053512A",
    "US5061795A",
    "US5061800A",
    "US5064823A",
    "US5106742A",
    "US5122526A",
    "US5122606A",
    "US5126351A",
    "US5145684A",
    "US5155225A",
    "US5162532A",
    "US5180722A",
    "US5225404A",
    "USRE32518E",
    "WO9105556A1",
    "WO9116904A1"
  ]
}